Background
ASCO and ONS, 2 leaders in adult-focused oncology, have been delineating evidence-based standards in chemotherapy administration safety since 2009 . Previous updates to the ASCO/ONS Chemotherapy Administration Safety Standards addressed inclusion of the inpatient practice setting (Jacobson et al., 2012) and the increased use of oral antineoplastic agents (Neuss et al., 2013) . With the understanding that the oncology world does not operate in silos, ASCO and ONS invited the Association of Pediatric Hematology/Oncology Nursing (APHON) and the American Society of Pediatric Hematology/Oncology (ASPHO) as key stakeholders invested in incorporating pediatric-specific considerations into the next evolution of the chemotherapy administration safety standards. The resulting work, the "2016 Updated American Society of Clinical Oncology/Oncology Nursing Society Chemotherapy Administration Safety Standards, Including Standards for Pediatric Oncology" has now been jointly published online by ASCO (www.asco.org/chemo-stan dards) and ONS (https://onf.ons.org/2016-updatedamerican-society-clinical-oncologyoncology-nursingsociety-chemotherapy-administration).
The updated 2016 chemotherapy safety standards clarify and expand on the existing standards as well as introduce new standards with the cumulative purpose of setting minimum expectations for ordering, preparing, administering, and monitoring chemotherapy in a variety of treatment settings and across all patient populations. While the standards should be read as a comprehensive set, the key pediatric considerations will be highlighted herein.
Domain 1: Creating a Safe Environment-Staffing and General Policy
This first section of the chemotherapy safety standards highlights training, education, and communication in key personnel involved in ordering, preparing, and delivering antineoplastic therapy. Standard 1.2 states, the health care setting uses a comprehensive education program for initial and ongoing educational requirements for all staff who prepare and administer chemotherapy. The APHON Pediatric Chemotherapy and Biotherapy Provider Course and Provider Renewal Program are APHON's dedicated nursing education programs for antineoplastic administration and patient management in the pediatric and young adult populations. Standard 1.3 adds the concept that clinical staff members present during chemotherapy administration must have age-appropriate life support training and certification.
This section also addresses essential elements for evaluation at a patient's presentation for chemotherapy administration. Standard 1.6 initiates the list of patient assessment elements required to be performed and documented on each clinical encounter or day of treatment. Due to the fluidity of pediatric growth and the subsequent impact on chemotherapy dosing, it is critical that variables such as weight and height are measured and documented at least 697670J POXXX10.1177/1043454217697670Journal of Pediatric Oncology NursingBelderson and Billett editorial2017 1 Children's Hospital Colorado, Aurora, CO, USA 2 Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA weekly in the health care setting (Standard 1.6.3; 1.6.4). Additionally, patient age is a significant variable in pediatric treatment plans; some pediatric plans change antineoplastic dosing parameters based on patient age, such as changing from weight-based to body surface area-based dosing at 12 months of age, and intrathecal chemotherapy dosing is often based solely on patient age. Standard 1.6.5 was added to include age as an essential element to document with each clinical encounter.
Finally, patient attendance at scheduled visits and/or chemotherapy treatments is necessary for successful treatment delivery. As parents/guardians or other adult caregivers predominantly are responsible for escorting pediatric patients to the treatment setting, it was important to incorporate a standard addressing our professional obligation for mandated reporting. Standard 1.10.1 introduces language that reflects our responsibility and accountability to ensure the best interest of the child is met, including seeking input from child protective services and/or the courts as needed to meet that duty.
Domain 2: Treatment Planning, Patient Consent, and Education
The second section delves into concepts in treatment planning and patient education before the initiation of treatment, including informed consent. While pediatric patients may not be entitled to provide legal informed consent for oncologic treatment, the notion of assent is fundamental to pediatric practice and thus was incorporated into the chemotherapy safety Standards 2.1 and 2.2 (Committee on Bioethics, 2016; Katz, Webb, & Committee on Bioethics, 2016). Additionally, as parents and/or guardians are integral to caring for pediatric patients, the term caregiver is incorporated into standards involving gathering information from or providing education to the patient (Standard 1.5.5; 2.4). As noted in the glossary for all the standards, the definition of patient has been expanded to include not only the recipient of health care but also parents and other caregivers as appropriate. Thus, the standards now clearly address the pediatric patient with the associated family unit.
Health literacy and cultural competence are core components in the education and information-sharing process between health care providers and patients/caregivers. Accordingly, Standard 2.4 states, educational activities will be performed on the basis of the patient's learning needs abilities, preferences, and readiness to learn.
Since pediatric chemotherapy is delivered commonly in both the outpatient and home setting, the standards were enhanced to address the safe handling of antineoplastic medications and body waste (i.e., diapers) in the home (Standard 2.3.7; 2.3.8).
Domain 3: Ordering, Preparing, Dispensing, and Administering Chemotherapy
Section 3 guides the clinical staff on specific safety principles involved in ordering, preparing (including labeling), and administering chemotherapy. Errors involving ordering, preparation, and administration of chemotherapy agents are a serious safety risk for all populations; however, the risk may be more significant in pediatric patients where there can be many-fold variation in both intended dosages of commonly used drugs and patient dosing parameters, as well as changes in patient dosing parameters over time, and vastly different metabolism of drugs in neonates versus older adolescents. Many pediatric treatment plans incorporate cycles in which oral chemotherapy agents are to be administered daily for days, weeks, or months at a time. Some of these agents, such as mercaptopurine, require periodic dose adjustments due to changes in patient physiologic function. These changes may occur between visits. The process of communicating the dose change and ensuring patient/caregiver understanding of the change presents considerable potential for error. Thus, Standard 3.5.2 was added to clarify the need for providers to communicate dose adjustments directly to patients and document all changes to ongoing treatment in the medical record.
The importance of independent verifications in chemotherapy ordering, preparation, and administration is featured in Standards 3.10 and 3.11. Although chemotherapy management in adult ambulatory settings may not include a pharmacist, Standard 3.10 requires a licensed pharmacist verify all orders before dispensing and/or administering chemotherapy in health care settings that treat patients younger than 18 years. The 10-to 100-fold variation in dosing parameters, final doses, diluents, and rates in pediatrics requires the input of all three disciplines to ensure safe care. Standard 3.11 pinpoints three times when independent verifications are required:
(1) before preparation, (2) on preparation, and (3) before administration. The inclusion of independently verifying infusion/drug volume and pump programming settings, both of which are important elements for safe chemotherapy administration in pediatric patients, is present in Standards 3.11.3.3 and 3.11.3.8.
Vincristine, an intravenous vinca alkaloid agent, is used ubiquitously in treatment of pediatric malignancies. Vinca alkaloids are fatal if administered intrathecally. National safety measures have moved the preparation and administration of vinca alkaloids to small-volume infusion minibags as this further reduces the risk of administering vinca alkaloids, such as vincristine, by the incorrect route. Standard 3.15 now requires health care settings that administer both vinca alkaloid and intrathecal chemotherapy administer vinca alkaloids only by infusion. Additionally, Standard 3.14.14 specifies the need to ensure that only chemotherapy agents intended for administration into the central nervous system are delivered to the intrathecal procedure room.
Pediatric treatment plans may include home parenteral chemotherapy given by a home health nurse. Standard 3.20.1 addresses the importance of correct patient identification when chemotherapy is administered in a nonhealth care setting by a health care provider.
Domain 4: Monitoring After Chemotherapy Is Administered, Including Adherence, Toxicity, and Complications
The final section discusses concepts of adherence and toxicity monitoring and management throughout and subsequent to the treatment process. Adherence in the pediatric and young adult populations is a significant concern to treatment outcomes (Bhatia et al., 2012; Hullmann, Brumley, & Schwartz, 2015; Landier, 2011) . Multiple factors affect treatment adherence throughout the span of chemotherapy treatment. It is the responsibility of the health care provider to maintain open and accessible communication with the patient/caregiver regarding adherence. Standards 4.3 and 4.4 were enhanced to elucidate the need for health care settings to have policies in place for initial and ongoing chemotherapy adherence assessments. Furthermore, as treatment-related toxicities can impact adherence, Standard 4.5 clarifies the process of evaluating and documenting toxicities, and any dose-related modifications due to the toxicities.
Conclusion
Evidence-based standards serve as the foundation for best practice and help ensure the culture of safety and quality that is a necessity in pediatric oncology practice. We encourage you to read and incorporate the comprehensive 2016 ASCO/ONS Chemotherapy Safety Standards as a means of optimizing safety in pediatric chemotherapy.
